Legal Representation
Attorney
Scott D. Woldow
USPTO Deadlines
Next Deadline
209 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
February 11, 2026
Extension Available
Until February 11, 2026
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 11, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 11, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jul 11, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 11, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 11, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 17, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 17, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 11, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 17, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 17, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 17, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Oct 17, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 17, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Oct 14, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 14, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 14, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 12, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 12, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 12, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 24, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 28, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 22, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals
Class 044
Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals
Additional Information
Pseudo Mark
THINK INTRAVENOUS IMMUNOGLOBULIN. WRITE PRIVIGEN
Classification
International Classes
035
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"IVIG"